Literature DB >> 16900511

Level-adjusted perioperative risk of sacral amputations.

Clinton Devin1, Paul Y Chong, Ginger E Holt, Irene Feurer, Adriana Gonzalez, Nipun Merchant, Herbert S Schwartz.   

Abstract

BACKGROUND AND OBJECTIVES: Sacral amputations above the S2 body often involve increased surgical complexity leading to long-term morbidity. The purpose of this study was to determine whether proximal sacral amputations have substantially higher perioperative morbidity compared with more distal sacral amputations.
METHODS: We evaluated the effect of sacral amputation level on perioperative outcomes within 90 days of surgery. Outcome measures included blood loss, intensive care unit (ICU) and hospital stay, hospital cost, and incidence of a major and minor morbidity. Survival analyses were adjusted for the level of resection and histological appearance.
RESULTS: Thirteen proximal and 14 distal resections were performed. In comparing proximal versus distal resections, median estimated blood loss was 4 L versus 1 L (P < 0.001), ICU stay was 4 days versus 0 days (P = 0.012), hospital stay was 19 days versus 8 days (P = 0.001), hospital cost was 28,800 dollars versus 7,500 dollars (P = 0.003), with one or more major complications in 85% versus 29% (P = 0.011). Survival analysis demonstrated that the sacral resection level did not influence survival (P = 0.936), whereas the type of tumor did influence survival (P = 0.012).
CONCLUSION: Tumor resections above S2 demonstrate increased perioperative morbidity, suggesting that proximal osteotomies be reserved for patients with a realistic cure potential. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16900511     DOI: 10.1002/jso.20477

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma.

Authors:  Matthias Uhl; Thomas Welzel; Alexandra Jensen; Malte Ellerbrock; Thomas Haberer; Oliver Jäkel; Klaus Herfarth; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2015-03-04       Impact factor: 3.621

2.  Surgical margins and local control in resection of sacral chordomas.

Authors:  Pietro Ruggieri; Andrea Angelini; Giuseppe Ussia; Maurizio Montalti; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

3.  Risk factors for blood loss during sacral tumor resection.

Authors:  Xiaodong Tang; Wei Guo; Rongli Yang; Shun Tang; Tao Ji
Journal:  Clin Orthop Relat Res       Date:  2008-09-10       Impact factor: 4.176

4.  Evaluation of blood loss during limb salvage surgery for pelvic tumours.

Authors:  Xiaodong Tang; Wei Guo; Rongli Yang; Shun Tang; Tao Ji
Journal:  Int Orthop       Date:  2008-12-17       Impact factor: 3.075

5.  Sacral insufficiency fractures after high-dose carbon-ion based radiotherapy of sacral chordomas.

Authors:  Tilman Bostel; Nils Henrik Nicolay; Thomas Welzel; Thomas Bruckner; Matthias Mattke; Sati Akbaba; Tanja Sprave; Jürgen Debus; Matthias Uhl
Journal:  Radiat Oncol       Date:  2018-08-23       Impact factor: 3.481

6.  Sacrococcygeal chordoma, a rare cause of coccygodynia.

Authors:  Paschalis Gavriilidis; Dimitrios Kyriakou
Journal:  Am J Case Rep       Date:  2013-12-19

7.  The unresolved case of sacral chordoma: from misdiagnosis to challenging surgery and medical therapy resistance.

Authors:  Fabio Garofalo; Dimitrios Christoforidis; Pietro G di Summa; Béatrice Gay; Stéphane Cherix; Wassim Raffoul; Nicolas Demartines; Maurice Matter
Journal:  Ann Coloproctol       Date:  2014-06-23

8.  Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol.

Authors:  Matthias Uhl; Lutz Edler; Alexandra D Jensen; Gregor Habl; Jan Oelmann; Falk Röder; Oliver Jäckel; Jürgen Debus; Klaus Herfarth
Journal:  Radiat Oncol       Date:  2014-04-29       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.